FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387333371> ?p ?o ?g. }

• W4387333371 abstract "Abstract Background Despite major improvements in treatment of HER2-positive metastatic breast cancer (MBC), only few patients achieve complete remission and remain progression free for a prolonged time. The tumor immune microenvironment plays an important role in the response to treatment in HER2-positive breast cancer and could contain valuable prognostic information. Detailed information on the cancer-immune cell interactions in HER2-positive MBC is however still lacking. By characterizing the tumor immune microenvironment in patients with HER2-positive MBC, we aimed to get a better understanding why overall survival (OS) differs so widely and which alternative treatment approaches may improve outcome. Methods We included all patients with HER2-positive MBC who were treated with trastuzumab-based palliative therapy in the Netherlands Cancer Institute between 2000 and 2014 and for whom pre-treatment tissue from the primary tumor or from metastases was available. Infiltrating immune cells and their spatial relationships to one another and to tumor cells were characterized by immunohistochemistry and multiplex immunofluorescence. We also evaluated immune signatures and other key pathways using next-generation RNA-sequencing data. With nine years median follow-up from initial diagnosis of MBC, we investigated the association between tumor and immune characteristics and outcome. Results A total of 124 patients with 147 samples were included and evaluated. The different technologies showed high correlations between each other. T-cells were less prevalent in metastases compared to primary tumors, whereas B-cells and regulatory T-cells (Tregs) were comparable between primary tumors and metastases. Stromal tumor-infiltrating lymphocytes in general were not associated with OS. The infiltration of B-cells and Tregs in the primary tumor was associated with unfavorable OS. Four signatures classifying the extracellular matrix of primary tumors showed differential survival in the population as a whole. Conclusions In a real-world cohort of 124 patients with HER2-positive MBC, B-cells, and Tregs in primary tumors are associated with unfavorable survival. With this paper, we provide a comprehensive insight in the tumor immune microenvironment that could guide further research into development of novel immunomodulatory strategies. Graphical Abstract" @default.
• W4387333371 created "2023-10-05" @default.
• W4387333371 creator A5005988887 @default.
• W4387333371 creator A5014135109 @default.
• W4387333371 creator A5016015665 @default.
• W4387333371 creator A5017612284 @default.
• W4387333371 creator A5027431241 @default.
• W4387333371 creator A5034253169 @default.
• W4387333371 creator A5035168675 @default.
• W4387333371 creator A5043980504 @default.
• W4387333371 creator A5047387130 @default.
• W4387333371 creator A5048535376 @default.
• W4387333371 creator A5056917101 @default.
• W4387333371 creator A5062190609 @default.
• W4387333371 creator A5068508825 @default.
• W4387333371 creator A5069636342 @default.
• W4387333371 creator A5071056994 @default.
• W4387333371 creator A5072143364 @default.
• W4387333371 creator A5076178845 @default.
• W4387333371 creator A5085962824 @default.
• W4387333371 date "2023-10-04" @default.
• W4387333371 modified "2023-10-18" @default.
• W4387333371 title "B-cells and regulatory T-cells in the microenvironment of HER2+ breast cancer are associated with decreased survival: a real-world analysis of women with HER2+ metastatic breast cancer" @default.
• W4387333371 cites W1992468678 @default.
• W4387333371 cites W2027941603 @default.
• W4387333371 cites W2053122486 @default.
• W4387333371 cites W2055746004 @default.
• W4387333371 cites W2077676209 @default.
• W4387333371 cites W2088160256 @default.
• W4387333371 cites W2096864872 @default.
• W4387333371 cites W2101824635 @default.
• W4387333371 cites W2104453868 @default.
• W4387333371 cites W2109107379 @default.
• W4387333371 cites W2114101532 @default.
• W4387333371 cites W2120431466 @default.
• W4387333371 cites W2121518671 @default.
• W4387333371 cites W2128985829 @default.
• W4387333371 cites W2130598050 @default.
• W4387333371 cites W2140948050 @default.
• W4387333371 cites W2141436376 @default.
• W4387333371 cites W2141929347 @default.
• W4387333371 cites W2143738177 @default.
• W4387333371 cites W2156711378 @default.
• W4387333371 cites W2156934935 @default.
• W4387333371 cites W2163035374 @default.
• W4387333371 cites W2177260001 @default.
• W4387333371 cites W2443444708 @default.
• W4387333371 cites W2510572197 @default.
• W4387333371 cites W2536419064 @default.
• W4387333371 cites W2559858344 @default.
• W4387333371 cites W2710688454 @default.
• W4387333371 cites W2740476111 @default.
• W4387333371 cites W2761452338 @default.
• W4387333371 cites W2766985996 @default.
• W4387333371 cites W2774455292 @default.
• W4387333371 cites W2805345499 @default.
• W4387333371 cites W2809333366 @default.
• W4387333371 cites W2890298773 @default.
• W4387333371 cites W2894546855 @default.
• W4387333371 cites W2902856530 @default.
• W4387333371 cites W2914643394 @default.
• W4387333371 cites W2914888321 @default.
• W4387333371 cites W2942790586 @default.
• W4387333371 cites W2950563001 @default.
• W4387333371 cites W2952406594 @default.
• W4387333371 cites W2956922351 @default.
• W4387333371 cites W2965988302 @default.
• W4387333371 cites W2967339341 @default.
• W4387333371 cites W2971394750 @default.
• W4387333371 cites W2980385048 @default.
• W4387333371 cites W2981420512 @default.
• W4387333371 cites W2981427923 @default.
• W4387333371 cites W2995808512 @default.
• W4387333371 cites W2996630100 @default.
• W4387333371 cites W2997592474 @default.
• W4387333371 cites W2999681746 @default.
• W4387333371 cites W3011002637 @default.
• W4387333371 cites W3011274212 @default.
• W4387333371 cites W3012380787 @default.
• W4387333371 cites W3016939709 @default.
• W4387333371 cites W3043237451 @default.
• W4387333371 cites W3088588360 @default.
• W4387333371 cites W3123743675 @default.
• W4387333371 cites W3195831375 @default.
• W4387333371 cites W3216448540 @default.
• W4387333371 cites W4206905957 @default.
• W4387333371 cites W4250310729 @default.
• W4387333371 doi "https://doi.org/10.1186/s13058-023-01717-1" @default.
• W4387333371 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37794508" @default.
• W4387333371 hasPublicationYear "2023" @default.
• W4387333371 type Work @default.
• W4387333371 citedByCount "0" @default.
• W4387333371 crossrefType "journal-article" @default.
• W4387333371 hasAuthorship W4387333371A5005988887 @default.
• W4387333371 hasAuthorship W4387333371A5014135109 @default.
• W4387333371 hasAuthorship W4387333371A5016015665 @default.
• W4387333371 hasAuthorship W4387333371A5017612284 @default.
• W4387333371 hasAuthorship W4387333371A5027431241 @default.
• W4387333371 hasAuthorship W4387333371A5034253169 @default.
• W4387333371 hasAuthorship W4387333371A5035168675 @default.

• next